Stocky turns companies like FUJI PHARMA CO LTD into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Cautious. 4554.T shows modest growth credentials (59/100 Growth Compounder Score) but lacks the earnings power or margin expansion needed to justify conviction. Leadership alignment is middling (52/100), and despite a low vulnerability score, the business remains structurally exposed — a combination that demands more visibility before committing capital.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for FUJI PHARMA CO LTD:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 42/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates FUJI PHARMA CO LTD (4554.T) at 42/100 — below the bar Stocky looks for. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Cautious. 4554.T shows modest growth credentials (59/100 Growth Compounder Score) but lacks the earnings power or margin expansion needed to justify conviction. Leadership alignment is middling (52/100), and despite a low vulnerability scor
4554.T's current Stocky Verdict is 42/100, placing it in the "Cautious" band. This composite combines a 59/100 Compounder score, 52/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for FUJI PHARMA CO LTD yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
FUJI PHARMA CO LTD scores 52/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
FUJI PHARMA CO LTD's Vulnerability Profile scores 0/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to FUJI PHARMA CO LTD.
Sign up free and unlock the full analysis on 4554.T — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for 4554.T in the app.
